Table 1.

Comparison between ACA+ SS and ACA–SS.

ACA+ SS, n = 26ACA–SS, n = 420p
Demographics
  Age, yrs, mean ± SD55.7 ± 10.553.2 ± 13.4NS
  Sex
  Male039NS
  Female26381NS
Clinical differences
  Prevalence of RP (%)8828< 0.001
Serological markers
  Prevalence of positive Ro/La antibodies (%)3577< 0.001
  Prevalence of elevated serum IgG (%)2457< 0.001
  Average levels of serum IgG, gm/l12.419.4< 0.001
Xerophthalmia
  Prevalence of xerophthalmia (%)9696NS
  Severity of xerophthalmia (on VAS, max 10)7 ± 2.46.4 ± 2.6NS
  Average van Bijsterveld score5.7 ± 2.25.6 ± 2.3NS
  Schirmer-I test, mm/5 min3.2 ± 1.84.2 ± 4.4< 0.05
  Duration, yrs, range5.4 (0–20)7.5 (0–50)NS
Xerostomia
  Prevalence of xerostomia (%)10098NS
  Severity of xerostomia (on VAS, max 10)8.5 ± 1.46.7 ± 2.4< 0.001
  USSF, ml/15 min0.10.4< 0.001
  Duration, yrs, range5.8 (0–22)6.8 (0–45)NS
Salivary gland biopsy
  Focus score ≥ 1 (%)9284< 0.001
  Average focus score5.5 ± 4.34.0 ± 3.3NS
  Average fibrosis score (out of 3)1.0 ± 0.821.1 ± 0.68NS
  • Normal serum IgG levels are 7–16 g/l in healthy patients. Rose bengal test evaluates ocular surface epithelial damage (out of 9). Schirmer-I test measures lacrimal gland production. Normal USSF ≥ 1.5 mm/15 min. Salivary gland biopsy positive result: ≥ 1 focus per 4 mm2. SS: Sjögren syndrome; ACA: anticentromere antibodies; NS: not significant; RP: Raynaud phenomenon; VAS: visual analog scale; USSF: unstimulated whole salivary flow.